Table 1.
Summary of three high-risk (hr)HPV triage strategies for detecting CIN2+ among women in South East District, Botswana.
Table 2.
Clinical and laboratory time, supplies, and capital costs per person screened (2022 US Dollars).
Table 3.
Costs, effectiveness, and incremental cost-effectiveness of true cases of CIN2 + detected among a cohort of 2,959 participants who received primary hrHPV screening followed by three triage strategies among 1,269 participants who screened positive for high-risk HPV in Botswana.
Fig 1.
(A) Primary hrHPV screen, which includes the genotyping triage strategy for those who screened positive. Genotyping has no additional cost. (B) The additional cost of adding VIA as a triage screen for those who screened positive using the hrHPV assay. (C) The additional cost of adding colposcopy as a triage screen for those who screened positive using the hrHPV assay.
Fig 2.
Post-hoc analysis examining the cost-effectiveness plane of three HPV triage strategies including varied short-term treatment for true and false positive CIN2+ .